Summary
SARS-CoV-2 (CoV-2), which surfaced in late 2019 in Wuhan City, China, most likely originated in bats and rapidly spread among humans globally, harming and disrupting livelihoods worldwide. Early into the pandemic, reports of CoV-2 diagnoses in pets and other animals emerged, including dogs, cats, farmed mink and some large felids (tigers and lions) from various countries. While most CoV-2 positive animals were confirmed to have been in close contact with CoV-2 positive humans, there has been a paucity of published evidence to-date describing risk factors associated with CoV-2 transmission among humans and domestic and wild animals. The COVID-19 Human-Animal Interactions Survey (CHAIS) was developed through a cross-CEIRS Center collaboration to provide a standardized survey describing human-animal interaction during the pandemic and to evaluate behavioral, spatiotemporal, and biological risk factors associated with bi-directional zoonotic transmission of CoV-2 within households and other shared environments. CHAIS measures four broad domains of transmission risk; 1) intensity and risk of infection among human hosts, 2) spatial characteristics of shared environments, 3) behaviors and human-animal interactions, and 4) animal susceptibility to infection and propensity for onward spread. Following the development of CHAIS, with a One Health approach, a multidisciplinary group of experts (n=20) was invited to review and provide feedback on the survey for content validity. Expert feedback was incorporated into two final survey formats-a long-form and an abridged version for which specific core questions addressing zoonotic and reverse zoonotic transmission were identified. Both forms are modularized, with each section having the capacity to serve as independent instruments, allowing researchers to customize the survey based on context and research-specific needs. Further adaptations for studies seeking to investigate other zoonotic pathogens with similar routes of transmission (i.e. respiratory, direct contact) are also possible. The CHAIS instrument is a standardized human-animal interaction survey developed to provide important data on risk factors that guide transmission of CoV-2 from humans to animals, with great utility in capturing information of zoonotic transmission risk factors for CoV-2 and other similar pathogens.
Impacts
We present a standardized survey instrument for evaluating risk factors associated with bi-directional zoonotic transmission of SARS-CoV-2 and other similarly transmitted pathogens in household and other settings where humans and animals share close contact.
The CHAIS instrument evaluates behavioral, spatiotemporal, and host determinants of transmission risk of SARS-CoV-2 and is highly adaptable for use in studies seeking to investigate other zoonotic pathogens such as influenza viruses.
This standardized instrument will enable pooling of data across studies for meta-analyses to improve predictive models of bi-directional transmission of SARS-CoV-2 among humans and animals and will inform public health prevention and mitigation measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the NIH Centers of Excellence in Influenza Research and Surveillance (HHSN272201400007C), which also provided support for JDG and JAR. MFD was supported by the National Institutes of Health (K01OD019918 to M.F.D.). KBW was supported by Eunice Kennedy Shriver National Institute of Child Health & Development (R01HD097692)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB oversite was not necessary or required for this body of work.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
Authors can confirm that all relevant data are included in the article and/or its supplementary information files.